Author + information
- S1936879815020853-9272e1a650a4b71a86d44e0418dbec7fGiovanna Sarno1,
- S1936879815020853-ad35a42a0f99f66f627537390d9406c0Bo Lagerqvist1,
- S1936879815020853-d5315321e6379b6b2d70ddc12a9636adGöran Olivecrona2,
- S1936879815020853-8bb6c2172f290b703bb6e9835550ddbbChristoph Varenhorst1,
- S1936879815020853-8ac97a234abbbf8ebcb43b69b427bde9Mikael Danielewicz3,
- S1936879815020853-1a06e593bdf840e2b1af78f77d74cf72Kristina Hambraeus4,
- S1936879815020853-535010ac99ec70932e19a12b82aff3ddAgneta Johansson5,
- S1936879815020853-e2807568f6428b4e4e3616784b8335dbTruls Råmunddal6,
- S1936879815020853-dd4c4b5e5ebec6a377465d05b6055307Nils Witt7 and
- S1936879815020853-d20fd22b7e864386e8cc76c9595181d8Stefan James1
- 1Cardiology department and Uppsala Clinical Research Center, Uppsala, Sweden
- 2Department of Cardiology, Lund University, Lund, Sweden
- 3Cardiology department, Karlstad, Sweden
- 4Cardiology department, Falun, Sweden
- 5Cardiology department, Sunderbyn, Sweden
- 6Cardiology department, Gothenburg, Sweden
- 7Cardiology department Södersjukhuset, Stockholm, Sweden
In unselected patients from a nationwide registry we describe the initial real-world experience with a novel everolimus eluting platinum chromium stent with biodegradable polymer (SYNERGY).
All implanted SYNERGY stents were compared to all new generation DES (n-DES) with more than 1000 implantations in Sweden between March 2013 and October 2015. The results were assessed using propensity score and Cox regression analyses. A subgroup analysis was performed in patients with acute coronary syndromes (ACS).
A total of 7,886 of SYNERGY stents and 58,004 other n-DES (BioMatrix, N=1,953; Orsiro, N= 4,946; Promus Element Plus, N= 2,543; Promus Premier, N= 20,414; Xience Xpedition, N= 7971, Resolute/Resolute Integrity, N=19021; Ultimaster, N=1156; Resolute Onyx, N=6425) were implanted during 42,357 procedures. The baseline clinical and procedural characteristics are shown in table 1. Restenosis occurred in 525 and ST in 282 cases, respectively, in the total population up to 1 year. The cumulative rate of restenosis up to 1 year in the Synergy group was not significantly different from the other n-DES group (1.2% vs. 1.0%, adjusted HR: 1.24 95% CI: 0.88-1.75; p=0.21). The cumulative rate of ST up to 1 year in the Synergy group was low and not significantly different from the other n-DES group (0.2% vs. 0.5%, adjusted HR: 0.68; 95% CI: 0.38-1.19; p=0.17). No ST events were observed in the Synergy group after 6 months.
Similarly in ACS patients, there was no significant difference in ST rates up to 1 year between SYNERGY and other n-DES (0.3% vs. 0.7%; adjusted HR: 0.69; 95% CI: 0.37-1.37; p=0.29).
In a large real-world population the SYNERGY stent appears to be safe and effective with a low rate of restenosis and ST comparable with other n-DES. The risk of ST up to 1 year is similarly low also in patients with ACS.
|Age, years, mean||68.0 ± 10.8||67.6 ± 10.8||0.02|
|Women (%)||1191 (28.0)||9697 (25.4)||<0.01|
|Diabetes (%)||981 (23.1)||8346 (21.9)||<0.01|
|NSTEMI (%)||14384 (37.2)||14384 (37.7)||NS|
|STEMI (%)||1017 (23.9)||9261 (24.3)||NS|
|SA (%)||1031 (24.3)||9300 (24.4)||NS|
|UA (%)||412 (9.7)||3751 (9.8)||NS|